Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Merck & Co., Inc., commonly referred to as Merck, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in the United States. Founded in 1891, the company has established a strong presence in major operational regions, including North America, Europe, and Asia. Merck is renowned for its innovative research and development in areas such as oncology, vaccines, and infectious diseases, with core products like Keytruda and Gardasil setting benchmarks in their respective fields.
With a commitment to advancing global health, Merck has achieved significant milestones, including numerous FDA approvals and recognitions for its contributions to public health. The company’s robust pipeline and dedication to scientific excellence position it as a formidable force in the pharmaceutical landscape, making it a trusted name among healthcare professionals and patients alike.
+55 vs industry average
Merck And Co’s score of 97 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Merck And Co, a US-based Pharmaceutical Preparation Manufacturing company, reported its Scope 1 and Scope 2 emissions for 2025 as approximately 600,800 kg CO2e. For 2024, the company reported total Scope 1 emissions of approximately 721,200,000 kg CO2e, Scope 2 emissions (market-based) of around 163,000,000 kg CO2e, and Scope 3 emissions totalling approximately 6,057,900,000 kg CO2e.
Merck And Co is committed to significant climate action, with Science Based Targets initiative (SBTi) validated targets. The company aims to achieve net-zero greenhouse gas emissions across its entire value chain (Scopes 1, 2, and 3) by 2045, from a 2019 baseline. This long-term commitment aligns with a 1.5°C trajectory.
In the near term, Merck And Co plans to reduce its absolute Scope 1 and Scope 2 GHG emissions by 46% by 2030, also from a 2019 baseline. Additionally, the company is committed to reducing its absolute Scope 3 GHG emissions by 30% within the same timeframe. These targets cover biogenic emissions and removals from bioenergy feedstocks. The company reported a 12% reduction in Scope 1 and 2 emissions from its 2019 baseline in 2023, and a 4% decrease in Scope 3 emissions from its 2019 baseline in 2023. Merck And Co also aims to become carbon neutral across its operations (Scopes 1 and 2) by 2025.
2045
90% reduction in Scope 1
Merck & Co., Inc. commits to reduce absolute scope 1 GHG emissions 90% by 2045 from a 2019 base year.
2045
90% reduction in Scope 2
Merck & Co., Inc. commits to reduce absolute scope 2 GHG emissions 90% by 2045 from a 2019 base year.
2030
46.2% reduction in Scope 2
Merck & Co., Inc. commits to reduce absolute scope 2 GHG emissions 46.2% by 2030 from a 2019 base year.
See all 7 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Merck And Co’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more